ReP USP - Resultado da busca

Artigo de periodico-carta/editorial
ARHGAP6 transcript levels are associated with molecular risk and impact survival outcomes in acute myeloid leukemia (2024)
Silva, Jean Carlos Lipreri da ; Silva, Juan Luiz Coelho da ; Vicari, Hugo Passos ; Lima, Keli Cristina de ; Rego, Eduardo Magalhães ; Traina, Fabiola ; Machado Neto, João Agostinho
Fonte: Hematology, Transfusion and Cell Therapy. Unidades: FM, FMRP, ICB
Assuntos: FARMACOLOGIA, LEUCEMIA MIELOIDE AGUDA, MEDULA ÓSSEA, CÉLULAS SANGUÍNEAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SILVA, Jean Carlos Lipreri da et al. ARHGAP6 transcript levels are associated with molecular risk and impact survival outcomes in acute myeloid leukemia. Hematology, Transfusion and Cell Therapy. São José do Rio Preto: Faculdade de Medicina, Universidade de São Paulo. Disponível em: https://doi.org/10.1016/j.htct.2023.06.004. Acesso em: 05 jun. 2024. , 2024
APA
Silva, J. C. L. da, Silva, J. L. C. da, Vicari, H. P., Lima, K. C. de, Rego, E. M., Traina, F., & Machado Neto, J. A. (2024). ARHGAP6 transcript levels are associated with molecular risk and impact survival outcomes in acute myeloid leukemia. Hematology, Transfusion and Cell Therapy. São José do Rio Preto: Faculdade de Medicina, Universidade de São Paulo. doi:https://doi.org/10.1016/j.htct.2023.06.004
NLM
Silva JCL da, Silva JLC da, Vicari HP, Lima KC de, Rego EM, Traina F, Machado Neto JA. ARHGAP6 transcript levels are associated with molecular risk and impact survival outcomes in acute myeloid leukemia [Internet]. Hematology, Transfusion and Cell Therapy. 2024 ; 46( 1): 105-106.[citado 2024 jun. 05 ] Available from: https://doi.org/10.1016/j.htct.2023.06.004
Vancouver
Silva JCL da, Silva JLC da, Vicari HP, Lima KC de, Rego EM, Traina F, Machado Neto JA. ARHGAP6 transcript levels are associated with molecular risk and impact survival outcomes in acute myeloid leukemia [Internet]. Hematology, Transfusion and Cell Therapy. 2024 ; 46( 1): 105-106.[citado 2024 jun. 05 ] Available from: https://doi.org/10.1016/j.htct.2023.06.004
Artigo de periodico
Targeting PIP4K2 lipid kinases through Thz-P1-2 reveals vulnerabilities related to mitochondrial homeostasis and autophagy in acute leukemia (2022)
Lima, Keli ; Pereira-Martins Diego A. ; Miranda, Lívia Bassani Lins de ; Coelho-Silva, Juan L. ; Leandro, Giovana da Silva ; Isabel Weinhäuser ; Cavaglieri, Rita de Cássia ; Silva, Wellington F.; Leal, Aline Medeiros; Lange, Ana Paula Alencar de Lima; Velloso, Elvira Deolinda Rodrigues Pereira ; Griessinger, Emmanuel ; Hilberink, Jacobien R. ; Huls, Gerwin A. ; Schuringa, Jan Jacob ; Rego, Eduardo M. ; Machado Neto, João Agostinho
Fonte: Blood. Unidades: FM, ICB, FMRP
Assuntos: FARMACOLOGIA, LEUCEMIA MIELOIDE AGUDA, NEOPLASIAS POR TIPO HISTOLÓGICO, AMINOÁCIDOS, PROTEÍNAS QUINASES, DANO AO DNA, MITOCÔNDRIAS, HOMEOSTASE, LISOSSOMOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
LIMA, Keli et al. Targeting PIP4K2 lipid kinases through Thz-P1-2 reveals vulnerabilities related to mitochondrial homeostasis and autophagy in acute leukemia. Blood, v. 140, p. 5965–5966, 2022Tradução . . Disponível em: https://doi.org/10.1182/blood-2022-165172. Acesso em: 05 jun. 2024.
APA
Lima, K., Pereira-Martins Diego A.,, Miranda, L. B. L. de, Coelho-Silva, J. L., Leandro, G. da S., Isabel Weinhäuser,, et al. (2022). Targeting PIP4K2 lipid kinases through Thz-P1-2 reveals vulnerabilities related to mitochondrial homeostasis and autophagy in acute leukemia. Blood, 140, 5965–5966. doi:10.1182/blood-2022-165172
NLM
Lima K, Pereira-Martins Diego A., Miranda LBL de, Coelho-Silva JL, Leandro G da S, Isabel Weinhäuser, Cavaglieri R de C, Silva WF, Leal AM, Lange APA de L, Velloso EDRP, Griessinger E, Hilberink JR, Huls GA, Schuringa JJ, Rego EM, Machado Neto JA. Targeting PIP4K2 lipid kinases through Thz-P1-2 reveals vulnerabilities related to mitochondrial homeostasis and autophagy in acute leukemia [Internet]. Blood. 2022 ; 140 5965–5966.[citado 2024 jun. 05 ] Available from: https://doi.org/10.1182/blood-2022-165172
Vancouver
Lima K, Pereira-Martins Diego A., Miranda LBL de, Coelho-Silva JL, Leandro G da S, Isabel Weinhäuser, Cavaglieri R de C, Silva WF, Leal AM, Lange APA de L, Velloso EDRP, Griessinger E, Hilberink JR, Huls GA, Schuringa JJ, Rego EM, Machado Neto JA. Targeting PIP4K2 lipid kinases through Thz-P1-2 reveals vulnerabilities related to mitochondrial homeostasis and autophagy in acute leukemia [Internet]. Blood. 2022 ; 140 5965–5966.[citado 2024 jun. 05 ] Available from: https://doi.org/10.1182/blood-2022-165172
Artigo de periodico
Differential cytotoxic activity of pharmacological inhibitors of IGF1R-related pathways in JAK2V617F driven cells (2022)
Fernandes, Jaqueline Cristina; Fenerich, Bruna Alves ; Silva, Antônio Bruno Alves; Fonseca, Natasha Peixoto ; Silva, Juan Luiz Coelho ; Scheucher, Priscila Santos ; Rego, Eduardo Magalhães ; Pontes, Lorena Lôbo Figueiredo ; Machado Neto, João Agostinho ; Traina, Fabiola
Fonte: Toxicology in Vitro. Unidades: FM, FMRP, ICB
Assuntos: FARMACOLOGIA, ANTINEOPLÁSICOS, INIBIDORES QUÍMICOS, MEDULA ÓSSEA, CÉLULAS-TRONCO, PROLIFERAÇÃO CELULAR, APOPTOSE, MUTAÇÃO, CÉLULAS MIELOIDES, FATORES DE CRESCIMENTO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
FERNANDES, Jaqueline Cristina et al. Differential cytotoxic activity of pharmacological inhibitors of IGF1R-related pathways in JAK2V617F driven cells. Toxicology in Vitro, v. 83, p. 1-7, 2022Tradução . . Disponível em: https://doi.org/10.1016/j.tiv.2022.105384. Acesso em: 05 jun. 2024.
APA
Fernandes, J. C., Fenerich, B. A., Silva, A. B. A., Fonseca, N. P., Silva, J. L. C., Scheucher, P. S., et al. (2022). Differential cytotoxic activity of pharmacological inhibitors of IGF1R-related pathways in JAK2V617F driven cells. Toxicology in Vitro, 83, 1-7. doi:10.1016/j.tiv.2022.105384
NLM
Fernandes JC, Fenerich BA, Silva ABA, Fonseca NP, Silva JLC, Scheucher PS, Rego EM, Pontes LLF, Machado Neto JA, Traina F. Differential cytotoxic activity of pharmacological inhibitors of IGF1R-related pathways in JAK2V617F driven cells [Internet]. Toxicology in Vitro. 2022 ; 83 1-7.[citado 2024 jun. 05 ] Available from: https://doi.org/10.1016/j.tiv.2022.105384
Vancouver
Fernandes JC, Fenerich BA, Silva ABA, Fonseca NP, Silva JLC, Scheucher PS, Rego EM, Pontes LLF, Machado Neto JA, Traina F. Differential cytotoxic activity of pharmacological inhibitors of IGF1R-related pathways in JAK2V617F driven cells [Internet]. Toxicology in Vitro. 2022 ; 83 1-7.[citado 2024 jun. 05 ] Available from: https://doi.org/10.1016/j.tiv.2022.105384
Artigo de periodico
Suppression of multiple anti-apoptotic BCL2 family proteins recapitulates the effects of JAK2 inhibitors in JAK2V617F driven myeloproliferative neoplasms (2022)
Takei, Hisashi; Silva, Juan Luiz Coelho ; Leal, Cristina Tavares; Rocha, Adriana Queiroz Arantes; Bianco, Thiago Mantello ; Welner, Robert S.; Mishima, Yuta ; Kobayashi, Ikei S.; Mullally, Ann ; Lima, Keli Cristina de ; Machado Neto, João Agostinho ; Kobayashi, Susumu S. ; Pontes, Lorena Lobo De Figueiredo
Fonte: Cancer Science. Unidades: ICB, FMRP, FM
Assuntos: FARMACOLOGIA, PROTEÍNAS PROTO-ONCOGÊNICAS, INIBIDORES DE ENZIMAS, MODELOS ANIMAIS DE DOENÇAS, FÁRMACOS, MEDICAMENTO, NEOPLASIAS, PROLIFERAÇÃO CELULAR, SOBREVIVÊNCIA CELULAR, CAMUNDONGOS, MUTAÇÃO, APOPTOSE
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
TAKEI, Hisashi et al. Suppression of multiple anti-apoptotic BCL2 family proteins recapitulates the effects of JAK2 inhibitors in JAK2V617F driven myeloproliferative neoplasms. Cancer Science, v. 113, n. 2, p. 1-12, 2022Tradução . . Disponível em: https://doi.org/10.1111/cas.15210. Acesso em: 05 jun. 2024.
APA
Takei, H., Silva, J. L. C., Leal, C. T., Rocha, A. Q. A., Bianco, T. M., Welner, R. S., et al. (2022). Suppression of multiple anti-apoptotic BCL2 family proteins recapitulates the effects of JAK2 inhibitors in JAK2V617F driven myeloproliferative neoplasms. Cancer Science, 113( 2), 1-12. doi:10.1111/cas.15210
NLM
Takei H, Silva JLC, Leal CT, Rocha AQA, Bianco TM, Welner RS, Mishima Y, Kobayashi IS, Mullally A, Lima KC de, Machado Neto JA, Kobayashi SS, Pontes LLDF. Suppression of multiple anti-apoptotic BCL2 family proteins recapitulates the effects of JAK2 inhibitors in JAK2V617F driven myeloproliferative neoplasms [Internet]. Cancer Science. 2022 ; 113( 2): 1-12.[citado 2024 jun. 05 ] Available from: https://doi.org/10.1111/cas.15210
Vancouver
Takei H, Silva JLC, Leal CT, Rocha AQA, Bianco TM, Welner RS, Mishima Y, Kobayashi IS, Mullally A, Lima KC de, Machado Neto JA, Kobayashi SS, Pontes LLDF. Suppression of multiple anti-apoptotic BCL2 family proteins recapitulates the effects of JAK2 inhibitors in JAK2V617F driven myeloproliferative neoplasms [Internet]. Cancer Science. 2022 ; 113( 2): 1-12.[citado 2024 jun. 05 ] Available from: https://doi.org/10.1111/cas.15210
Artigo de periodico
Comprehensive analysis of cytoskeleton regulatory genes identifies ezrin as a prognostic marker and molecular target in acute myeloid leukemia (2021)
Silva, Jean Carlos Lipreri da ; Silva, Juan Luiz Coelho ; Lima, Keli ; Vicari, Hugo Passos ; Lazarini, Mariana ; Lotufo, Leticia Veras Costa ; Traina, Fabiola ; Machado Neto, João Agostinho
Fonte: Cellular Oncology. Unidades: ICB, FMRP
Assuntos: FARMACOLOGIA, LEUCEMIA MIELOIDE AGUDA, ANTINEOPLÁSICOS, CITOESQUELETO, EXPRESSÃO GÊNICA, GENÔMICA, TRANSDUÇÃO DE SINAL CELULAR
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SILVA, Jean Carlos Lipreri da et al. Comprehensive analysis of cytoskeleton regulatory genes identifies ezrin as a prognostic marker and molecular target in acute myeloid leukemia. Cellular Oncology, v. 44, n. 5, p. 1105-1117, 2021Tradução . . Disponível em: https://doi.org/10.1007/s13402-021-00621-0. Acesso em: 05 jun. 2024.
APA
Silva, J. C. L. da, Silva, J. L. C., Lima, K., Vicari, H. P., Lazarini, M., Lotufo, L. V. C., et al. (2021). Comprehensive analysis of cytoskeleton regulatory genes identifies ezrin as a prognostic marker and molecular target in acute myeloid leukemia. Cellular Oncology, 44( 5), 1105-1117. doi:10.1007/s13402-021-00621-0
NLM
Silva JCL da, Silva JLC, Lima K, Vicari HP, Lazarini M, Lotufo LVC, Traina F, Machado Neto JA. Comprehensive analysis of cytoskeleton regulatory genes identifies ezrin as a prognostic marker and molecular target in acute myeloid leukemia [Internet]. Cellular Oncology. 2021 ; 44( 5): 1105-1117.[citado 2024 jun. 05 ] Available from: https://doi.org/10.1007/s13402-021-00621-0
Vancouver
Silva JCL da, Silva JLC, Lima K, Vicari HP, Lazarini M, Lotufo LVC, Traina F, Machado Neto JA. Comprehensive analysis of cytoskeleton regulatory genes identifies ezrin as a prognostic marker and molecular target in acute myeloid leukemia [Internet]. Cellular Oncology. 2021 ; 44( 5): 1105-1117.[citado 2024 jun. 05 ] Available from: https://doi.org/10.1007/s13402-021-00621-0
Artigo de periodico
Molecular-based score inspired on metabolic signature improves prognostic stratification for myelodysplastic syndrome (2021)
Silva, Juan Luiz Coelho ; Silveira, Douglas Rafaele Almeida ; Martins, Diego Antonio Pereira ; Rojas, Cesar A. O.; Araujo, Antonio R. Lucena ; Rego, Eduardo Magalhães ; Machado Neto, João Agostinho ; Bendit, Israel ; Rocha, Vanderson Geraldo ; Traina, Fabiola
Fonte: Scientific Reports. Unidades: FM, ICB, FMRP
Assuntos: FARMACOLOGIA, FARMACOGENÉTICA, EXPRESSÃO GÊNICA, CICLO CELULAR, MEDULA ÓSSEA, DOENÇAS SANGUÍNEAS E LINFÁTICAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SILVA, Juan Luiz Coelho et al. Molecular-based score inspired on metabolic signature improves prognostic stratification for myelodysplastic syndrome. Scientific Reports, v. 11, p. 11 , 2021Tradução . . Disponível em: https://doi.org/10.1038/s41598-020-80918-6. Acesso em: 05 jun. 2024.
APA
Silva, J. L. C., Silveira, D. R. A., Martins, D. A. P., Rojas, C. A. O., Araujo, A. R. L., Rego, E. M., et al. (2021). Molecular-based score inspired on metabolic signature improves prognostic stratification for myelodysplastic syndrome. Scientific Reports, 11, 11 . doi:10.1038/s41598-020-80918-6
NLM
Silva JLC, Silveira DRA, Martins DAP, Rojas CAO, Araujo ARL, Rego EM, Machado Neto JA, Bendit I, Rocha VG, Traina F. Molecular-based score inspired on metabolic signature improves prognostic stratification for myelodysplastic syndrome [Internet]. Scientific Reports. 2021 ; 11 11 .[citado 2024 jun. 05 ] Available from: https://doi.org/10.1038/s41598-020-80918-6
Vancouver
Silva JLC, Silveira DRA, Martins DAP, Rojas CAO, Araujo ARL, Rego EM, Machado Neto JA, Bendit I, Rocha VG, Traina F. Molecular-based score inspired on metabolic signature improves prognostic stratification for myelodysplastic syndrome [Internet]. Scientific Reports. 2021 ; 11 11 .[citado 2024 jun. 05 ] Available from: https://doi.org/10.1038/s41598-020-80918-6
Artigo de periodico
STMN1 is highly expressed and contributes to clonogenicity in acute promyelocytic leukemia cells (2021)
Vicari, Hugo Passos ; Silva, Juan Luiz Coelho da ; Martins, Diego Antonio Pereira ; Araujo, Antônio Roberto Lucena de ; Lima, Keli Cristina de ; Silva, Jean Carlos Lipreri da ; Scheucher, Priscila Santos ; Koury, Luisa C.; Melo, Raul A. de ; Bittencourt, Rosane; Pagnano, Katia ; Nunes, Elenaide ; Fagundes, Evandro Maranhão ; Kerbauy, Fabio; Pontes, Lorena Lobo de Figueiredo ; Lotufo, Leticia Veras Costa ; Rego, Eduardo Magalhães ; Traina, Fabiola ; Machado Neto, João Agostinho
Fonte: Investigational New Drugs. Unidades: FMRP, ICB, FM
Assuntos: FARMACOLOGIA, CÉLULAS SANGUÍNEAS, CLONAGEM, LEUCEMIA MIELOIDE AGUDA, ONCOPROTEÍNAS, CÉLULAS MIELOIDES, CICLO CELULAR, HEMATOPOESE
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
VICARI, Hugo Passos et al. STMN1 is highly expressed and contributes to clonogenicity in acute promyelocytic leukemia cells. Investigational New Drugs, p. 1-15, 2021Tradução . . Disponível em: https://doi.org/10.1007/s10637-021-01197-0. Acesso em: 05 jun. 2024.
APA
Vicari, H. P., Silva, J. L. C. da, Martins, D. A. P., Araujo, A. R. L. de, Lima, K. C. de, Silva, J. C. L. da, et al. (2021). STMN1 is highly expressed and contributes to clonogenicity in acute promyelocytic leukemia cells. Investigational New Drugs, 1-15. doi:10.1007/s10637-021-01197-0
NLM
Vicari HP, Silva JLC da, Martins DAP, Araujo ARL de, Lima KC de, Silva JCL da, Scheucher PS, Koury LC, Melo RA de, Bittencourt R, Pagnano K, Nunes E, Fagundes EM, Kerbauy F, Pontes LL de F, Lotufo LVC, Rego EM, Traina F, Machado Neto JA. STMN1 is highly expressed and contributes to clonogenicity in acute promyelocytic leukemia cells [Internet]. Investigational New Drugs. 2021 ; 1-15.[citado 2024 jun. 05 ] Available from: https://doi.org/10.1007/s10637-021-01197-0
Vancouver
Vicari HP, Silva JLC da, Martins DAP, Araujo ARL de, Lima KC de, Silva JCL da, Scheucher PS, Koury LC, Melo RA de, Bittencourt R, Pagnano K, Nunes E, Fagundes EM, Kerbauy F, Pontes LL de F, Lotufo LVC, Rego EM, Traina F, Machado Neto JA. STMN1 is highly expressed and contributes to clonogenicity in acute promyelocytic leukemia cells [Internet]. Investigational New Drugs. 2021 ; 1-15.[citado 2024 jun. 05 ] Available from: https://doi.org/10.1007/s10637-021-01197-0
Artigo de periodico
NT157, an IGF1R-IRS1/2 inhibitor, exhibits antineoplastic effects in pre-clinical models of chronic myeloid leukemia (2021)
Ribeiro, Renata Scopim ; Machado Neto, João Agostinho ; Eide, Christopher A. ; Silva, Juan Luiz Coelho da ; Fenerich, Bruna Alves ; Fernandes, Jaqueline Cristina; Scheucher, Priscila Santos ; Stevens, Samantha L. Savage ; Campos, Paula de Melo; Saad, Sara T. Olalla ; Palma, Leonardo de Carvalho ; Pontes, Lorena Lobo de Figueiredo ; Simões, Belinda Pinto ; Rego, Eduardo Magalhães ; Tognon, Cristina E. ; Druker, Brian J. ; Traina, Fabiola
Fonte: Investigational New Drugs. Unidades: ICB, FMRP, FM
Assuntos: FARMACOLOGIA, LEUCEMIA MIELOIDE, INSULINA, ANTINEOPLÁSICOS, PROTEÍNAS QUINASES, CÉLULAS SANGUÍNEAS, PROLIFERAÇÃO CELULAR, APOPTOSE, ONCOGENES
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
RIBEIRO, Renata Scopim et al. NT157, an IGF1R-IRS1/2 inhibitor, exhibits antineoplastic effects in pre-clinical models of chronic myeloid leukemia. Investigational New Drugs, v. 39, n. 3, p. 736-746, 2021Tradução . . Disponível em: https://doi.org/10.1007/s10637-020-01028-8. Acesso em: 05 jun. 2024.
APA
Ribeiro, R. S., Machado Neto, J. A., Eide, C. A., Silva, J. L. C. da, Fenerich, B. A., Fernandes, J. C., et al. (2021). NT157, an IGF1R-IRS1/2 inhibitor, exhibits antineoplastic effects in pre-clinical models of chronic myeloid leukemia. Investigational New Drugs, 39( 3), 736-746. doi:10.1007/s10637-020-01028-8
NLM
Ribeiro RS, Machado Neto JA, Eide CA, Silva JLC da, Fenerich BA, Fernandes JC, Scheucher PS, Stevens SLS, Campos P de M, Saad STO, Palma L de C, Pontes LL de F, Simões BP, Rego EM, Tognon CE, Druker BJ, Traina F. NT157, an IGF1R-IRS1/2 inhibitor, exhibits antineoplastic effects in pre-clinical models of chronic myeloid leukemia [Internet]. Investigational New Drugs. 2021 ; 39( 3): 736-746.[citado 2024 jun. 05 ] Available from: https://doi.org/10.1007/s10637-020-01028-8
Vancouver
Ribeiro RS, Machado Neto JA, Eide CA, Silva JLC da, Fenerich BA, Fernandes JC, Scheucher PS, Stevens SLS, Campos P de M, Saad STO, Palma L de C, Pontes LL de F, Simões BP, Rego EM, Tognon CE, Druker BJ, Traina F. NT157, an IGF1R-IRS1/2 inhibitor, exhibits antineoplastic effects in pre-clinical models of chronic myeloid leukemia [Internet]. Investigational New Drugs. 2021 ; 39( 3): 736-746.[citado 2024 jun. 05 ] Available from: https://doi.org/10.1007/s10637-020-01028-8
Artigo de periodico
Autophagy inhibition potentiates ruxolitinib-induced apoptosis in JAK2V617F cells (2020)
Machado Neto, João Agostinho ; Silva, Juan Luiz Coelho da ; Santos, Fábio Pires de Souza ; Scheucher, Priscila Santos ; Campregher, Paulo Vidal ; Hamerschlak, Nelson ; Rego, Eduardo Magalhães ; Traina, Fabiola
Fonte: Investigational New Drugs. Unidades: ICB, FMRP
Assuntos: FARMACOLOGIA, APOPTOSE, LEUCEMIA MIELOIDE AGUDA, NEOPLASIAS POR TIPO HISTOLÓGICO, ANTIMALÁRICOS, CÉLULAS MIELOIDES, CÉLULAS SANGUÍNEAS, ERITRÓCITOS, MUTAÇÃO GENÉTICA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
MACHADO NETO, João Agostinho et al. Autophagy inhibition potentiates ruxolitinib-induced apoptosis in JAK2V617F cells. Investigational New Drugs, v. 38, p. 733–745, 2020Tradução . . Disponível em: https://doi.org/10.1007/s10637-019-00812-5. Acesso em: 05 jun. 2024.
APA
Machado Neto, J. A., Silva, J. L. C. da, Santos, F. P. de S., Scheucher, P. S., Campregher, P. V., Hamerschlak, N., et al. (2020). Autophagy inhibition potentiates ruxolitinib-induced apoptosis in JAK2V617F cells. Investigational New Drugs, 38, 733–745. doi:10.1007/s10637-019-00812-5
NLM
Machado Neto JA, Silva JLC da, Santos FP de S, Scheucher PS, Campregher PV, Hamerschlak N, Rego EM, Traina F. Autophagy inhibition potentiates ruxolitinib-induced apoptosis in JAK2V617F cells [Internet]. Investigational New Drugs. 2020 ; 38 733–745.[citado 2024 jun. 05 ] Available from: https://doi.org/10.1007/s10637-019-00812-5
Vancouver
Machado Neto JA, Silva JLC da, Santos FP de S, Scheucher PS, Campregher PV, Hamerschlak N, Rego EM, Traina F. Autophagy inhibition potentiates ruxolitinib-induced apoptosis in JAK2V617F cells [Internet]. Investigational New Drugs. 2020 ; 38 733–745.[citado 2024 jun. 05 ] Available from: https://doi.org/10.1007/s10637-019-00812-5
Trabalho de evento-resumo periodico
Irs1S57X heterozygous mutant mice display normal hematopoiesis and phenotypic features, while homozygous knockout exhibit high fetal or postnatal lethality (2020)
Fenerich, Bruna Alves ; Fernandes, Jaqueline Cristina; Silva, Cleide Lúcia Araújo; Coelho-Silva, Juan Luiz; Silva, Antônio Bruno Alves; Fonseca, Natasha Peixoto; Machado Neto, João Agostinho ; Traina, Fabiola
Fonte: Blood. Nome do evento: ASH Annual Meeting and Exposition. Unidades: ICB, FMRP
Assuntos: HEMATOPOESE, TRANSTORNOS MIELOPROLIFERATIVOS, NEOPLASIAS, GENES, FENÓTIPOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
FENERICH, Bruna Alves et al. Irs1S57X heterozygous mutant mice display normal hematopoiesis and phenotypic features, while homozygous knockout exhibit high fetal or postnatal lethality. Blood. Washington: Instituto de Ciências Biomédicas, Universidade de São Paulo. Disponível em: https://doi.org/10.1182/blood-2020-139422. Acesso em: 05 jun. 2024. , 2020
APA
Fenerich, B. A., Fernandes, J. C., Silva, C. L. A., Coelho-Silva, J. L., Silva, A. B. A., Fonseca, N. P., et al. (2020). Irs1S57X heterozygous mutant mice display normal hematopoiesis and phenotypic features, while homozygous knockout exhibit high fetal or postnatal lethality. Blood. Washington: Instituto de Ciências Biomédicas, Universidade de São Paulo. doi:10.1182/blood-2020-139422
NLM
Fenerich BA, Fernandes JC, Silva CLA, Coelho-Silva JL, Silva ABA, Fonseca NP, Machado Neto JA, Traina F. Irs1S57X heterozygous mutant mice display normal hematopoiesis and phenotypic features, while homozygous knockout exhibit high fetal or postnatal lethality [Internet]. Blood. 2020 ; 136 [3] .[citado 2024 jun. 05 ] Available from: https://doi.org/10.1182/blood-2020-139422
Vancouver
Fenerich BA, Fernandes JC, Silva CLA, Coelho-Silva JL, Silva ABA, Fonseca NP, Machado Neto JA, Traina F. Irs1S57X heterozygous mutant mice display normal hematopoiesis and phenotypic features, while homozygous knockout exhibit high fetal or postnatal lethality [Internet]. Blood. 2020 ; 136 [3] .[citado 2024 jun. 05 ] Available from: https://doi.org/10.1182/blood-2020-139422
Artigo de periodico
Reversine exerts cytotoxic effects through multiple cell death mechanisms in acute lymphoblastic leukemia (2020)
Carlos, Jorge Antonio Elias Godoy; Lima, Keli ; Silva, Juan Luiz Coelho da ; Paiva, Raquel de Melo Alves ; Moreno, Natália Cestari ; Vicari, Hugo Passos ; Santos, Fábio Pires de Souza ; Hamerschlak, Nelson ; Traina, Fabiola ; Lotufo, Leticia Veras Costa ; Machado Neto, João Agostinho
Fonte: Cellular Oncology (Dordrecht, 2011). Unidades: FMRP, ICB, IQ, FM
Assuntos: FARMACOLOGIA, APOPTOSE, LEUCEMIA MIELOIDE AGUDA, MITOSE, NEOPLASIAS, PURINAS, EXPRESSÃO GÊNICA, LINFÓCITOS, PROLIFERAÇÃO CELULAR, DANO AO DNA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
CARLOS, Jorge Antonio Elias Godoy et al. Reversine exerts cytotoxic effects through multiple cell death mechanisms in acute lymphoblastic leukemia. Cellular Oncology (Dordrecht, 2011), v. 43, n. 6, p. 1191-1201, 2020Tradução . . Disponível em: https://doi.org/10.1007/s13402-020-00551-3. Acesso em: 05 jun. 2024.
APA
Carlos, J. A. E. G., Lima, K., Silva, J. L. C. da, Paiva, R. de M. A., Moreno, N. C., Vicari, H. P., et al. (2020). Reversine exerts cytotoxic effects through multiple cell death mechanisms in acute lymphoblastic leukemia. Cellular Oncology (Dordrecht, 2011), 43( 6), 1191-1201. doi:10.1007/s13402-020-00551-3
NLM
Carlos JAEG, Lima K, Silva JLC da, Paiva R de MA, Moreno NC, Vicari HP, Santos FP de S, Hamerschlak N, Traina F, Lotufo LVC, Machado Neto JA. Reversine exerts cytotoxic effects through multiple cell death mechanisms in acute lymphoblastic leukemia [Internet]. Cellular Oncology (Dordrecht, 2011). 2020 ; 43( 6): 1191-1201.[citado 2024 jun. 05 ] Available from: https://doi.org/10.1007/s13402-020-00551-3
Vancouver
Carlos JAEG, Lima K, Silva JLC da, Paiva R de MA, Moreno NC, Vicari HP, Santos FP de S, Hamerschlak N, Traina F, Lotufo LVC, Machado Neto JA. Reversine exerts cytotoxic effects through multiple cell death mechanisms in acute lymphoblastic leukemia [Internet]. Cellular Oncology (Dordrecht, 2011). 2020 ; 43( 6): 1191-1201.[citado 2024 jun. 05 ] Available from: https://doi.org/10.1007/s13402-020-00551-3
Artigo de periodico
NT157 has antineoplastic effects and inhibits IRS1/2 and STAT3/5 in JAK2V617F-positive myeloproliferative neoplasm cells (2020)
Fenerich, Bruna Alves ; Fernandes, Jaqueline Cristina; Alves, Ana Paula Nunes Rodrigues; Silva, Juan Luiz Coelho da ; Ribeiro, Renata Scopim; Scheucher, Priscila Santos ; Eide, Christopher A.; Tognon, Cristina E.; Druker, Brian J. ; Rego, Eduardo Magalhães ; Machado Neto, João Agostinho ; Traina, Fabiola
Fonte: Signal Transduction and Targeted Therapy. Unidades: FMRP, FM, ICB
Assuntos: FARMACOLOGIA, TRANSDUÇÃO DE SINAL CELULAR, CÉLULAS CULTIVADAS DE TUMOR, ANTINEOPLÁSICOS, PROLIFERAÇÃO CELULAR, ERITROPOIETINA, APOPTOSE, MUTAÇÃO GENÉTICA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
FENERICH, Bruna Alves et al. NT157 has antineoplastic effects and inhibits IRS1/2 and STAT3/5 in JAK2V617F-positive myeloproliferative neoplasm cells. Signal Transduction and Targeted Therapy, p. 10 , 2020Tradução . . Disponível em: https://doi.org/10.1038/s41392-019-0102-5. Acesso em: 05 jun. 2024.
APA
Fenerich, B. A., Fernandes, J. C., Alves, A. P. N. R., Silva, J. L. C. da, Ribeiro, R. S., Scheucher, P. S., et al. (2020). NT157 has antineoplastic effects and inhibits IRS1/2 and STAT3/5 in JAK2V617F-positive myeloproliferative neoplasm cells. Signal Transduction and Targeted Therapy, 10 . doi:10.1038/s41392-019-0102-5
NLM
Fenerich BA, Fernandes JC, Alves APNR, Silva JLC da, Ribeiro RS, Scheucher PS, Eide CA, Tognon CE, Druker BJ, Rego EM, Machado Neto JA, Traina F. NT157 has antineoplastic effects and inhibits IRS1/2 and STAT3/5 in JAK2V617F-positive myeloproliferative neoplasm cells [Internet]. Signal Transduction and Targeted Therapy. 2020 ; 10 .[citado 2024 jun. 05 ] Available from: https://doi.org/10.1038/s41392-019-0102-5
Vancouver
Fenerich BA, Fernandes JC, Alves APNR, Silva JLC da, Ribeiro RS, Scheucher PS, Eide CA, Tognon CE, Druker BJ, Rego EM, Machado Neto JA, Traina F. NT157 has antineoplastic effects and inhibits IRS1/2 and STAT3/5 in JAK2V617F-positive myeloproliferative neoplasm cells [Internet]. Signal Transduction and Targeted Therapy. 2020 ; 10 .[citado 2024 jun. 05 ] Available from: https://doi.org/10.1038/s41392-019-0102-5
Artigo de periodico
IGF1R/IRS1 targeting has cytotoxic activity and inhibits PI3K/AKT/mTOR and MAPK signaling in acute lymphoblastic leukemia cells (2019)
Alves, Ana Paula Nunes Rodrigues; Fernandes, Jaqueline Cristina; Fenerich, Bruna Alves ; Silva, Juan Luiz Coelho da; Scheucher, Priscila Santos ; Simões, Belinda Pinto ; Rego, Eduardo Magalhaes ; Ridley, Anne J. ; Machado Neto, João Agostinho ; Traina, Fabiola
Fonte: Cancer Letters. Unidades: FMRP, FM, ICB
Assuntos: LEUCEMIA, CÉLULAS SANGUINEAS, CITOTOXINAS, APOPTOSE, CÉLULAS CULTIVADAS DE TUMOR, ONCOGENES
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
ALVES, Ana Paula Nunes Rodrigues et al. IGF1R/IRS1 targeting has cytotoxic activity and inhibits PI3K/AKT/mTOR and MAPK signaling in acute lymphoblastic leukemia cells. Cancer Letters, v. 456, p. 59-68, 2019Tradução . . Disponível em: https://doi.org/10.1016/j.canlet.2019.04.030. Acesso em: 05 jun. 2024.
APA
Alves, A. P. N. R., Fernandes, J. C., Fenerich, B. A., Silva, J. L. C. da, Scheucher, P. S., Simões, B. P., et al. (2019). IGF1R/IRS1 targeting has cytotoxic activity and inhibits PI3K/AKT/mTOR and MAPK signaling in acute lymphoblastic leukemia cells. Cancer Letters, 456, 59-68. doi:10.1016/j.canlet.2019.04.030
NLM
Alves APNR, Fernandes JC, Fenerich BA, Silva JLC da, Scheucher PS, Simões BP, Rego EM, Ridley AJ, Machado Neto JA, Traina F. IGF1R/IRS1 targeting has cytotoxic activity and inhibits PI3K/AKT/mTOR and MAPK signaling in acute lymphoblastic leukemia cells [Internet]. Cancer Letters. 2019 ; 456 59-68.[citado 2024 jun. 05 ] Available from: https://doi.org/10.1016/j.canlet.2019.04.030
Vancouver
Alves APNR, Fernandes JC, Fenerich BA, Silva JLC da, Scheucher PS, Simões BP, Rego EM, Ridley AJ, Machado Neto JA, Traina F. IGF1R/IRS1 targeting has cytotoxic activity and inhibits PI3K/AKT/mTOR and MAPK signaling in acute lymphoblastic leukemia cells [Internet]. Cancer Letters. 2019 ; 456 59-68.[citado 2024 jun. 05 ] Available from: https://doi.org/10.1016/j.canlet.2019.04.030
Artigo de periodico
PIP4K2A and PIP4K2C transcript levels are associated with cytogenetic risk and survival outcomes in acute myeloid leukemia (2019)
Lima, Keli Cristina de ; Silva, Juan Luiz Coelho da ; Kinker, Gabriela Sarti ; Pereira-Martins, Diego Antonio; Traina, Fabiola ; Fernandes, Pedro Augusto Carlos Magno ; Markus, Regina P ; Lucena-Araújo, Antonio Roberto Lucena; Machado Neto, João Agostinho
Fonte: Cancer Genetics. Unidades: FMRP, IB, ICB, FM
Assuntos: LEUCEMIA MIELOIDE, LIPÍDEOS, CITOGENÉTICA, PROTEÍNAS QUINASES, LIPÍDEOS, TRANSCRIÇÃO GÊNICA, MICRORNAS, EXPRESSÃO GÊNICA, RNA, GENÔMICA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
LIMA, Keli Cristina de et al. PIP4K2A and PIP4K2C transcript levels are associated with cytogenetic risk and survival outcomes in acute myeloid leukemia. Cancer Genetics, v. 233-234, p. 56-66, 2019Tradução . . Disponível em: https://doi.org/10.1016/j.cancergen.2019.04.002. Acesso em: 05 jun. 2024.
APA
Lima, K. C. de, Silva, J. L. C. da, Kinker, G. S., Pereira-Martins, D. A., Traina, F., Fernandes, P. A. C. M., et al. (2019). PIP4K2A and PIP4K2C transcript levels are associated with cytogenetic risk and survival outcomes in acute myeloid leukemia. Cancer Genetics, 233-234, 56-66. doi:10.1016/j.cancergen.2019.04.002
NLM
Lima KC de, Silva JLC da, Kinker GS, Pereira-Martins DA, Traina F, Fernandes PACM, Markus RP, Lucena-Araújo ARL, Machado Neto JA. PIP4K2A and PIP4K2C transcript levels are associated with cytogenetic risk and survival outcomes in acute myeloid leukemia [Internet]. Cancer Genetics. 2019 ; 233-234 56-66.[citado 2024 jun. 05 ] Available from: https://doi.org/10.1016/j.cancergen.2019.04.002
Vancouver
Lima KC de, Silva JLC da, Kinker GS, Pereira-Martins DA, Traina F, Fernandes PACM, Markus RP, Lucena-Araújo ARL, Machado Neto JA. PIP4K2A and PIP4K2C transcript levels are associated with cytogenetic risk and survival outcomes in acute myeloid leukemia [Internet]. Cancer Genetics. 2019 ; 233-234 56-66.[citado 2024 jun. 05 ] Available from: https://doi.org/10.1016/j.cancergen.2019.04.002
Artigo de periodico
Insulin Substrate Receptor (IRS) proteins in normal and malignant hematopoiesis (2018)
Machado Neto, João Agostinho ; Fenerich, Bruna Alves; Alves, Ana Paula Nunes Rodrigues; Fernandes, Jaqueline Cristina; Scopim-Ribeiro, Renata; Coelho-Silva, Juan Luiz ; Traina, Fabiola
Fonte: Clinics. Unidades: ICB, FMRP
Assuntos: RECEPTORES DE INSULINA, LEUCEMIA, HEMATOPOESE, NEOPLASIAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
MACHADO NETO, João Agostinho et al. Insulin Substrate Receptor (IRS) proteins in normal and malignant hematopoiesis. Clinics, v. 73, n. Suppl 1, 2018Tradução . . Disponível em: https://doi.org/10.6061/clinics/2018/e566s. Acesso em: 05 jun. 2024.
APA
Machado Neto, J. A., Fenerich, B. A., Alves, A. P. N. R., Fernandes, J. C., Scopim-Ribeiro, R., Coelho-Silva, J. L., & Traina, F. (2018). Insulin Substrate Receptor (IRS) proteins in normal and malignant hematopoiesis. Clinics, 73( Suppl 1). doi:10.6061/clinics/2018/e566s
NLM
Machado Neto JA, Fenerich BA, Alves APNR, Fernandes JC, Scopim-Ribeiro R, Coelho-Silva JL, Traina F. Insulin Substrate Receptor (IRS) proteins in normal and malignant hematopoiesis [Internet]. Clinics. 2018 ; 73( Suppl 1):[citado 2024 jun. 05 ] Available from: https://doi.org/10.6061/clinics/2018/e566s
Vancouver
Machado Neto JA, Fenerich BA, Alves APNR, Fernandes JC, Scopim-Ribeiro R, Coelho-Silva JL, Traina F. Insulin Substrate Receptor (IRS) proteins in normal and malignant hematopoiesis [Internet]. Clinics. 2018 ; 73( Suppl 1):[citado 2024 jun. 05 ] Available from: https://doi.org/10.6061/clinics/2018/e566s

Unidades USP

ReP

Filtros

Autores

Autores USP

Ano de publicação

Assuntos

Título da fonte

Agência de fomento

Indexado em

Afiliação dos autores externos não normalizada

País das instituições de afiliação dos autores externos